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INTRODUCTION:  Intra-gastric  balloons  have  been  in  use as  an  aide  to  weight  loss.  Since its introduction,  it
has  evolved  from  air  ﬁlled  to  saline  ﬁlled  intra-gastric  balloons.  The  SPATZ-ABS  is a new  adjustable  saline
ﬁlled  balloon.
PRESENTATION  OF  CASE:  Three  patients  have presented  to our  hospital  as  emergencies  due  to  compli-
cations  arising  from  this  balloon.  Two  of these  patients  required  emergency  laparotomy  and  resection
of  small  bowel  due  to pressure  necrosis  effects  of the  anchoring  device.  One  patient  had  migration  of
the  device  into  the  duodenum  that  was  removed  endoscopically.  Of  the 2  patients  who  underwent  a
laparotomy,  one  patient  did  not  have  any  symptoms  or  signs  that  correlated  with  the  intra-operativeigration
nfarction
esection
ﬁndings.
DISCUSSION:  The  anchoring  device  meant  to prevent  the  intra-gastric  balloon  from  migrating  distally  has
migrated  in  three  patients.  To our  knowledge,  there  has been  no  reported  incident  of migration  of  this
device.  These  serious  complications  pose  a  risk  to patients  having  these  balloons  ﬁtted.
CONCLUSION: There  is a need  to  study  our  experience  with  a  larger  population  of patients  who  have  had
this  device  inserted.  Its  safety  needs  to be questioned  and  its  design  may  need  to  be addressed.
©  2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. . Introduction
Obesity has been a growing concern worldwide. There is a spec-
rum of measures to aid with weight loss, ranging from dietary
odulation to surgical measures. Intra-gastric balloons are one of
he modalities studied and currently in practice. Intra-gastric bal-
oons have been in use since the 1980s. During the evolution of
ts use, complications arose from air ﬁlled balloons, including bal-
oon deﬂation and passage from the stomach into the small bowel
ubsequently causing bowel obstruction. It went out of favour for
everal years before being reintroduced as ﬂuid ﬁlled intra-gastric
alloons. We  report three cases of intra-gastric SPATZ balloon com-
lications. All three patients presented with symptoms of proximal
mall bowel obstruction. Two patients had jejunal resection as a
esult of pressure necrosis to the bowel by the anchoring device
f the SPATZ balloon. One patient had gastric ulceration with the
nchoring device migrating into the second part of the duodenum.
n all three cases, the balloon was intact and had not deﬂated. In
ll cases the balloon was in the stomach for less than the rec-
mmended one year period. We  recommend further studies to
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210-2612 © 2013 The Authors. Published by Elsevier Ltd on behalf of Surgical Associate
ttp://dx.doi.org/10.1016/j.ijscr.2013.07.025study the experience with these adjustable balloons with anchor-
ing devices in a larger series of patients. There is a need to relook
at the design again or even the recommended duration.
2.  Case series
2.1.  Case 1
A  31 year old lady with a history of asthma and a previous
gastric band that had been removed. She underwent an insertion
of a SPATZ-ABS intra-gastric balloon in a private hospital, seven
months prior to presentation to our hospital. She developed a
‘burning’ epigastric and left upper quadrant abdominal pain, which
had been progressively worsening. One week prior to admission,
she had started vomiting. Clinically she was mildly tender over
the left upper quadrant of her abdomen, but not peritonitic. An
urgent gastroscopy was  performed. This demonstrated the gastric
balloon itself to be in the stomach but the anchoring device had
migrated into the 3rd and 4th part of the duodenum, and could not
be retrieved endoscopically. She underwent an exploratory laparo-
tomy after a failed second attempt to remove the balloon device
under a general anaesthetic. The intact balloon was delivered by
a gastrotomy. However the anchoring device had migrated to the
duodeno-jejunal ﬂexure causing pressure necrotic changes to the
Open access under CC BY-NC-ND license.mesenteric and anti-mesenteric borders of the jejunal wall. This
device was  retrieved at the time of resection of the non-viable
jejunum. A functional anastomoses was created. The patient recov-
ered and was discharged on the 6th post-operative day.
s Ltd. Open access under CC BY-NC-ND license.
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.2. Case 2
A  42 year old lady with a previous history of curative surgery
or cervical cancer, sought to decrease weight. She had a SPATZ-
BS intra-gastric balloon inserted in a private hospital. Towards the
nd of the 11th month, she had a planned endoscopy to remove the
alloon. However, during the procedure to remove the intra-gastric
alloon, the anchoring device had migrated to the 3rd and 4th part
f the duodenum. The intra-gastric balloon itself was deﬂated and
he patient was referred to the emergency surgical admissions of
he hospital for an open retrieval of the device. She did not have any
bdominal symptoms or signs prior to surgery, except for a rise in
er CRP. She underwent an emergency laparotomy to retrieve the
evice.
At laparotomy, it was noted that the balloon device had migrated
urther into the duodeno-jejunal ﬂexure. There was evidence of
ressure necrosis to this segment of bowel. This segment was
esected and a functional anastomoses was created. She made an
neventful recovery and was discharged on the 7th postoperative
ay.
.3. Case 3
A  50 year old lady who was ﬁt and well, had a SPATZ-ABS
ntra-gastric balloon inserted in a private hospital. In the seventh
onth, she started developing symptoms of vomiting 2–3 h after
ating. These symptoms lasted for a week. Additionally, she devel-
ped epigastric and right upper quadrant pain before presenting to
he hospital with abdominal discomfort and acute kidney injury.
he was adequately resuscitated, and underwent an urgent gas-
roscopy, which demonstrated that the balloon was  still intact but
he anchoring device had migrated into the ﬁrst and second part of
he duodenum. There was evidence of a gastric ulcer at the incisura.
he gastric balloon was deﬂated at the time of the ﬁrst gastroscopy,
ut the device could not be retrieved on the same day. The patient
nderwent a repeat endoscopy the following day, when the device
as completely removed. She was started on antacids and was
ischarged on the same day.
. Discussion
There is no doubt that obesity is a growing problem worldwide.
n 2010, the World Health Organization reported that 43 million
hildren (35 million in developing countries) were estimated to
e overweight and obese.1 The key ﬁndings of the Heath Survey of
ngland in 2011, demonstrated that 24% men  and 26% women were
bese, with 41% of men  and 33% of women being overweight.2
There are different management options available to these
atients, ranging from lifestyle and dietary modiﬁcations, gastric
anding, sleeve gastrectomy and intra-gastric balloons. Intra-
astric balloons have been in practice since the 1980s when it was
rst introduced.3 It was  suggested that patients who had intra-
astric balloons would have an increased sense of satiety and a
educed oral intake. As it is easy to insert, modify and retrieve, it
roved attractive to doctors and patients. This however has been
ubject to debate, with some papers suggesting that the weight
oss for patients with intra-gastric balloons is comparable to those
ho had dietary manipulation alone.4,5 These initial studies were
onducted in the 1980s, and the intra-gastric balloons has evolved
ince.
The initial intra-gastric balloon models were ﬁlled with air. With
ime, it was noticed that the balloons did not come without compli-
ations. There were side effects associated with these balloons. The
ost common side effects were nausea, difﬁculty with inﬂating or
eﬂating the balloon, deﬂation and migration of the balloon, whichPEN  ACCESS
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in  some cases may  lead to obstruction.6 To address this concern,
experts convened at a conference to determine the ideal char-
acteristics of a safe and effective intra-gastric balloon.6 Based on
research and evidence available at the time, it was agreed that bal-
loons should be ﬁlled with ﬂuid instead of air, and that methylene
blue should be present in this ﬂuid, as any leakage of ﬂuid would
be identiﬁed by excretion of methylene blue by the patient.7 Since
then, various other ﬂuid and air ﬁlled intra-gastric balloons have
been in use worldwide.
Some  of the known complications of the intra-gastric bal-
loons are gastric ulceration in 2.5%, intolerance in 5%, difﬁculty in
inﬂating or deﬂating the balloon in 28.7% and spontaneous deﬂa-
tion of the balloon causing subsequent obstruction.8 There have
been many reports of intra-gastric balloons that have deﬂated and
migrated leading to bowel obstruction of variable degree. Balloons
have passed uneventfully,9,10 or caused gastric outlet obstruction
symptoms,11 spontaneous deﬂation of the balloon and even partial
bowel obstruction.12 In most of these reports, there was  balloon
deﬂation in about 80%, which again defers from our series.
The  general recommendation for most intra-gastric balloons, is
that it should be removed in 6 months, to reduce complications. In
2011, a pilot trial of the use of the intra-gastric SPATZ Adjustable
Balloon System (SPATZ-ABS) in 18 patients was  performed.13 Seven
of the eighteen patients had premature removal of the balloon
for gastritis (1), valve malfunction (1), Mallory-Weiss tear (1), bal-
loon deﬂation (1), NSAID perforating ulcer (1) and 2 patients who
had a catheter shear from the chain (one passed uneventfully and
the other causing esophageal laceration without perforation). The
follow up at one year for these patients demonstrated that only
one patient had a perforated ulcer, and this patient was  on NSAIDs.
However, the study population is small and a conclusion on the
safety of leaving the balloon in for one year cannot be assumed.
The  SPATZ-ABS anchoring device is unique in its aim to prevent
the migration of the balloon. However this anchoring device has
had serious complications to these three patients. To our knowl-
edge, there have been no reports on the migration of an anchoring
device. In our case series, two  patients had bowel resection as a
result of the migration of the anchoring device, despite the intra-
gastric balloon being intact in the stomach. With the reversal of
roles between the anchoring device and the balloon, the balloon
may act as an anchor whilst allowing the anchoring device to cause
pressure necrosis on the proximal small intestine, and eventu-
ally perforation. This is especially so at acute angles where the
metal anchoring device may  not pass easily. Even with the bal-
loon deﬂated, this anchoring device has caused irreparable damage
to the proximal small bowel which in these patients, was near the
duodeno-jejunal ﬂexure. What is of more concern is that, in the case
of one patient where there were no symptoms or signs. With our
experience from the ﬁrst two  patients, the last patients symptoms
were identiﬁed early and the patient was  treated before further
damage was done warranting emergency surgery. In all three cases,
the recommended duration of one year had not been exceeded.
Two patients developed complications that were life threatening,
with one patient treated before the anchoring device migrated any
further distally.
4.  Conclusion
Though intra-gastric balloons are safe and the SPATZ –
Adjustable Balloon System (ABS) is more amenable to modiﬁca-
tions once inserted with adequate weight loss, we question its
safety. We  suggest larger studies to report on experiences with
these balloons. We  urge the manufacturers to rectify this risk by
either modiﬁcation of either the design or the duration it is left in
situ.
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